Arbutus Biopharma (ABUS) Receives Daily Media Impact Score of 0.07

News headlines about Arbutus Biopharma (NASDAQ:ABUS) have trended somewhat positive this week, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Arbutus Biopharma earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.4164618487729 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

A number of analysts recently commented on the stock. JMP Securities reiterated an “outperform” rating and issued a $13.00 target price (up from $12.00) on shares of Arbutus Biopharma in a report on Wednesday, October 4th. Chardan Capital reiterated a “buy” rating on shares of Arbutus Biopharma in a report on Wednesday, September 13th. Zacks Investment Research upgraded shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a report on Tuesday, November 7th. Wedbush reiterated an “outperform” rating and issued a $9.00 target price on shares of Arbutus Biopharma in a report on Wednesday, September 20th. Finally, ValuEngine downgraded shares of Arbutus Biopharma from a “hold” rating to a “sell” rating in a report on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus target price of $13.00.

Arbutus Biopharma (NASDAQ ABUS) traded up $0.30 during midday trading on Tuesday, hitting $4.75. 337,200 shares of the company were exchanged, compared to its average volume of 239,205. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03. Arbutus Biopharma has a twelve month low of $2.35 and a twelve month high of $8.25.

In other news, insider Michael J. Sofia sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 3rd. The shares were sold at an average price of $8.00, for a total transaction of $80,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 6.90% of the stock is owned by insiders.

COPYRIGHT VIOLATION NOTICE: “Arbutus Biopharma (ABUS) Receives Daily Media Impact Score of 0.07” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://sportsperspectives.com/2017/12/19/arbutus-biopharma-abus-receives-daily-media-impact-score-of-0-07.html.

About Arbutus Biopharma

Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).

Insider Buying and Selling by Quarter for Arbutus Biopharma (NASDAQ:ABUS)

Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply